Quark reports results from diabetic macular edema drug study
The prospective randomised Phase 2 trial enrolled 184 patients who were randomised to receive three dose levels of PF-04523655 (0.4mg, 1mg, and 3mg) or laser photocoagulation control –
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.